Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery?

Archives of Internal Medicine

Volumn 162, Issue 13, 2002, Pages 1451-1456

  Strebel, Niklaus ^a   Prins, Martin ^a   Agnelli, Giancarlo ^b   Büller, Harry R ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ELECTIVE SURGERY; FEMALE; HIP SURGERY; HUMAN; IMMOBILIZATION; MAJOR CLINICAL STUDY; MALE; ORTHOPEDIC SURGERY; PHLEBOGRAPHY; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROPHYLAXIS; REGIONAL ANESTHESIA; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0037043245     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.162.13.1451     Document Type: Review

References (51)

1. Prevention of deep vein thrombosis after elective hip surgery: A randomized trial comparing low molecular weight heparin with standard unfractionated heparin
2. Prophylactically equivalent doses of enoxaparin and unfractionated heparin inhibit in vivo coagulation to the same extent
3. Enoxaparin prophylaxis in elective hip surgery
4. A Synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement
5. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery: A placebo controlled study
6. Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery
7. Low molecular weight heparin (enoxaparin) compared with unfractionated heparin in prophylaxis of deep venous thrombosis and pulmonary embolism in patients undergoing hip replacement
8. Comparison between low-molecular and unfractionated heparin in the prevention of thrombosis in patients with total endoprosthetic replacement of hip and knee joint
9. Perioperative low-molecular-weight heparin: Is it effective and safe?
10. The postdischarge prophylactic management of the orthopedic patient with low-molecular-weight heparin: Enoxaparin
11. Lowmolecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement
12. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty - The Danish Prolonged Prophylaxis (DaPP) Study
13. Comparison of the use of a foot pump with the use of low-molecularweight heparin for the prevention of deep-vein thrombosis after total hip replacement: A prospective, randomized trial
14. Prolonged thromboprophylaxis following hip replacement surgery - Results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin)
15. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery
16. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement: A clinical trial comparing efficacy and safety
17. Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery
18. Lowmolecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs inhospital warfarin/out-of-hospital placebo in hip arthroplasty patients: A double-blind, randomized comparison
19. The post-hospital discharge venous thrombosis risk of the orthopedic patient
20. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement: A prospective randomised double-blind placebocontrolled trial
21. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomised comparison of enoxaparin versus placebo
22. Comparison of two lowmolecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery
23. Efficacy and safety of a perioperative enoxaparin regimen in total hip replacement under various anesthesias
24. Doubleblind randomized comparative study of enoxaparin and standard heparin in the prevention of thromboembolic disease during insertion of total hip replacement
25. The use of enoxaparine in preventing deep venous thrombosis following total hip prosthesis: Randomized multicenter prospective trial
26. Efficacy of a postoperative regimen of enoxaparin in deep vein thrombosis prophylaxis
27. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery
28. Anticoagulant treatment of thromboembolism with intravenous heparin therapy in the early postoperative period following total joint arthroplasty
29. Potentials risks in drug prevention of thrombosis-low-molecular-weight heparin versus standard heparin
30. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: A multi-institutional cohort study of patients who underwent hip or knee arthroplasty
31. The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: A cohort study of 1,984 patients
32. Intraoperative heparin in addition to postoperative low-molecular-weight heparin for thromboprophylaxis in total knee replacement
33. Bleeding complications with enoxaparin for deep venous thrombosis prophylaxis
34. Comparative double-blind study of two dosage regimens of lowmolecular weight heparin in elderly patients with a fracture of the neck of the femur
35. Is colour Doppler ultrasound a sensitive screening method in diagnosing deep vein thrombosis after hip surgery?
36. Low-molecularweight heparin (enoxaparin) vs dextran 70: The prevention of postoperative deep vein thrombosis after total hip replacement
37. Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty
38. Prevention of deepvein thrombosis and pulmonary embolism after total hip replacement: Comparison of lowmolecular-weight heparin and unfractionated heparin
39. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement
40. Prevention of deep-vein thrombosis after total hip arthroplasty: Comparison of warfarin and dalteparin
41. Lowmolecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: A double-blind, randomized comparison
42. Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement: A randomised controlled trial
43. Comparison of antithrombotic efficacy and haemorrhagic side-effects of clivarin versus enoxaparin in patients undergoing total hip replacement surgery
44. Prevention of deep vein thrombosis after hip replacement - Comparison between two low-molecular heparins, tinzaparin and enoxaparin
45. Once-daily dosing of enoxaparin (a low molecular weight heparin) in prevention of deep vein thrombosis after total hip replacement
46. Prevention of deep vein thrombosis after total hip replacement: The effect of lowmolecular-weight heparin with spinal and general anaesthesia
47. Prevention of postoperative venous thrombosis: A randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement
48. Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery
49. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery
50. Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement
51. A dose-response study of the factor VIIa/tissue factor inhibitor rNAPc2 in the prevention of postoperative venous thrombosis in patients undergoing total knee arthroplasty